Skip to main content

Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy

Feb 13, 2023 3:00 pm
Social Author Name
Dr. John Cush
Tweet Content
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×